Back to Search
Start Over
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
- Source :
-
European journal of haematology [Eur J Haematol] 2016 Jun; Vol. 96 (6), pp. 643-9. Date of Electronic Publication: 2015 Sep 18. - Publication Year :
- 2016
-
Abstract
- At present, very few data are available on deferasirox (DFX) in the treatment of patients with Philadelphia-negative myeloproliferative neoplasms in fibrotic phase (FP-MPN) and transfusion dependence. To address this issue, a retrospective analysis of 28 patients (22 male and 6 female) with FP-MPN and iron overload secondary to transfusion dependence was performed, based on patients enrolled in the database of our regional cooperative group who received treatment with DFX. DFX was started after a median interval from diagnosis of 12.8 months (IR 7.1-43.1) with median ferritin values of 1415 ng/mL (IR 1168-1768). Extra-hematological toxicity was reported in 16 of 28 patients (57.1%), but only two patients discontinued treatment due to toxicity. Among 26 patients evaluable for response (≥6 months of treatment), after a median treatment period of 15.4 months (IR 8.1-22.3), 11 patients (42.3%) achieved a stable and consistent reduction in ferritin levels <1000 ng/mL. As for hematological improvement, 6 of 26 patients (23%) showed a persistent (>3 months) rise of Hb levels >1.5 g/dL, with disappearance of transfusion dependence in four cases. Treatment with DFX is feasible and effective in FP-MPN with iron overload. Moreover, in this setting, an erythroid response can occur in a significant proportion of patients.<br /> (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Subjects :
- Aged
Benzoates administration & dosage
Benzoates adverse effects
Chelation Therapy
Deferasirox
Erythrocyte Indices
Female
Fibrosis
Follow-Up Studies
Humans
Iron Chelating Agents administration & dosage
Iron Chelating Agents adverse effects
Iron Overload blood
Iron Overload diagnosis
Male
Middle Aged
Myeloproliferative Disorders mortality
Myeloproliferative Disorders therapy
Retrospective Studies
Transfusion Reaction
Treatment Outcome
Triazoles administration & dosage
Triazoles adverse effects
Benzoates therapeutic use
Erythropoiesis drug effects
Iron Chelating Agents therapeutic use
Iron Overload drug therapy
Iron Overload etiology
Myeloproliferative Disorders complications
Myeloproliferative Disorders pathology
Triazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1600-0609
- Volume :
- 96
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- European journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 26277477
- Full Text :
- https://doi.org/10.1111/ejh.12674